Pupila dilatada fixa (síndrome de Urrets-Zavalia) após ceratoplastia lamelar profunda / Fixed dilated pupil (Urrets-Zavalia syndrome) after deep lamellar keratoplasty

A Síndrome de Urrets-Zavalia apresenta achados oculares bem descritos, porém sua fisiopatologia ainda é incerta. A isquemia iriana é o mecanismo proposto mais comum. Descrevemos dois casos submetidos à ceratoplastia lamelar profunda (CLP) realizadas pelo mesmo cirugião que desenvolveram a síndrome. No primeiro caso, a indicação cirúrgica foi para o tratamento de opacidade corneana e, no segundo, para o de ceratocone. No pós-operatório, ambos os pacientes evoluíram com pupila dilatada fixa que não regrediu totalmente apesar do tratamento administrado.

The Urrets-Zavalia Syndrome presents well described ocular findings, even though its physiopathology is still unsure. Iris ischemia is the most common proposing mechanism. We describe two cases that underwent deep lamellar keratoplasty (DLK) performed by the same surgeon and developed the syndrome. In the first case, the surgical indication was for corneal opacity treatment and, in the second case, for keratoconus treatment. During the post-operatory, both patients developed fixed dilated pupil, which didn't regress completely inspite of the onset treatment.

Postoperative subconjunctival corticosteroid injection to prevent pterygium recurrence.

PURPOSE: To report the outcome of postoperative subconjunctival injection of triamcinolone in eyes that underwent pterygium surgery and were at risk for recurrence. METHODS: Twelve eyes of 11 patients with primary (7 eyes) or recurrent (5 eyes) pterygia underwent excision and conjunctival autografting (4 eyes, 33.3%), amniotic membrane grafting (6 eyes, 50%), or both (2 eyes, 16.6%). All of these eyes had signs that were considered to be risk factors for recurrence (conjunctival inflammation, hemorrhage, granuloma, and fibrovascular proliferation); accordingly, they also underwent subconjunctival injection of triamcinolone. RESULTS: Among the 11 patients, there were 8 (72.7%) men and 3 (27.3%) women; the mean age was 41 years (range, 20-56 years). In 5 (41.7%) eyes, the pterygium was graded as T2 (intermediate) and in 7 (58.3%) eyes was graded as T3 (fleshy). The time between surgery and the first injection ranged from 2 to 5 weeks (mean, 3.4 weeks), and 1-3 injections were necessary (mean, 1.7) to achieve the desired effect. After injection, 1 (8.3%) eye developed inflammation, and 2 (16.7%) eyes from another patient developed intraocular hypertension that was controlled with a topical beta-blocker. The follow-up after the last injection ranged from 8 to 36 months (mean, 14.5 months); only 1 recurrence (grade 3) occurred during this period. CONCLUSIONS: The postoperative use of subconjunctival triamcinolone seems to benefit patients at increased risk of pterygium recurrence. It is relatively safe and is accompanied by few complications, but controlled and prospective studies are necessary to confirm its efficacy.